Preview

Медицинский Совет

Расширенный поиск

Пазопаниб – препарат первой линии терапии у больных с метастатическим раком почки

https://doi.org/10.21518/2079-701X-2018-10-70-76

Полный текст:

Аннотация

Пазопаниб (Вотриент®) – пероральный низкомолекулярный мультикиназный ингибитор, который в первую очередь ингибирует рецептор 1, 2 и 3 сосудистого эндотелиального фактора роста, рецепторы α и β тромбоцитарного фактора роста эндотелия и рецепторы c-kit-фактора стволовых клеток. В предварительных экспериментах с использованием моделей ангиогенеза у мышей и кроликов пазопаниб ингибировал ангиогенез, вызванный комбинированным фактором роста эндотелия сосудов и основным фактором роста фибробластов. Хотя препарат был разработан как терапевтический мультиопухолевый агент, в настоящее время во многих странах он одобрен для применения при распространенной саркоме мягких тканей и почечно-клеточном раке (ПКР). В мультицентровых рандомизированных исследованиях по изучению эффективности пазопаниба в качестве препарата первой линии у больных с метастатическим ПКР он продемонстрировал значительно лучшую безрецидивную выживаемость (БРВ) по сравнению с цитокиновой терапией и одинаковое время до прогрессирования в случае применения сунитиниба. Кроме того, побочные эффекты, такие как нарушение функции печени и артериальная гипертензия, как правило, управляемы, и с точки зрения качества жизни и экономической эффективности пазопаниб представляется более предпочтительным агентом по сравнению с другими альтернативными препаратами.

Об авторах

Б. Я. Алексеев
Национальный медицинский исследовательский центр радиологии Минздрава России
Россия

Доктор медицинских наук, профессор 

Москва



И. М. Шевчук
Национальный медицинский исследовательский центр радиологии Минздрава России
Россия

Кандидат медицинских наук 

Москва



Список литературы

1. Stukalin I, Alimohamed N, Heng DYC. Contemporary treatment of metastatic renal cell carcinoma. Oncol Rev, 2016, 10(1): 295.

2. McCormack PL. Pazopanib: a review of its use in the managementof advanced renal cell carcinoma. Drugs, 2014, 74(10): 1111–25.

3. European Medicines Agency. Votrient (pazopanib) 200 mg filmcoated tablet: summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 7 Nov 2016.

4. Novartis Pharmaceuticals Corporation. Votrient (pazopanib) tablets: US prescribing information. 2016. https://www.pharma.us.novartis.com. Accessed 7 Nov 2016.

5. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs, 2011, 71(4): 443–54.

6. Kumar R, CrouthamelMC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer, 2009, 101(10): 1717–23.

7. Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M. TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway. Cancer Immunol Res, 2018 Apr 26.

8. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res, 2009, 15(12): 4220–7.

9. Shetty AV, Matrana MR, Atkinson BJ, et al. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience. Clin Genitourin Cancer, 2014, 12(5): 348–53.

10. Xu C-F, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol, 2012, 23(9): 2470–1.

11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol, 2010, 28(6): 1061–8.

12. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer, 2013, 49(6): 1287–96.

13. Cella D, Pickard AS, Duh MS, et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer, 2012, 48(3): 311–23.

14. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med, 2013, 369(8): 722–31.

15. Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renalcell carcinoma with pazopanib versus sunitinib. N Engl J Med, 2014, 370(18): 1769–70.

16. Beaumont JL, Salsman JM, Diaz J, et al. Qualityadjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer, 2016, 122(7): 1108–15.

17. Escudier B, Porta C, Bono P, et al. Randomized, controlled, doubleblind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol, 2014, 32(14): 1412–8.

18. Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer, 2015, 51(10): 1293–302.

19. KimJH, Park I, Lee JL. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol. 2016, 78(2): 325–32.

20. Vogelzang NJ, Hackshaw MD, Hutson TE, et al. First-line and sequential use of pazopanib followed by mammalian target of rapamycin inhibitor therapy among patients with advanced renal cell carcinoma in a US community oncology setting. Clin Genitourin Cancer, 2015, 13(3): 210–7.

21. Matrana M, Bathala T, Campbell M, et al. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with firstline pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience. BJU Int, 2016, 118(2): 264–71.

22. Perez-Valderrama B, Arranz Arija JA, Rodriguez Sanchez A, et al. Validation of the international metastatic renal-cell carcinoma database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish oncologic genitourinary group (SOGUG) SPAZO study. Ann Oncol, 2016, 27(4): 706–11.

23. KimMJ, Park SH, Lee JL, et al. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. BMC Urol, 2016, 16(1): 46.

24. Galvis V, Chow S, Lawrence D, et al. Clinical practice outcomes of patients treated with pazopanib for metastatic renal cell cancer (mRCC) – 6 year experience at a referral centre in Manchester, UK [abstract no. 2763]. Eur J Cancer, 2013, 49 (Suppl 2).

25. Jain A, Canipari C, Haque F, et al. Liver toxicity associated with the use of pazopanib in renal cancer patients: UK teaching hospital experience [abstract no. 2604]. Eur J Cancer, 2015, 51(Suppl 3): S513.

26. Cecere SC, Rossetti S, Cavaliere C, et al. Pazopanib in metastatic renal cancer: a Breal-world experience at National Cancer Institute BFondazione G. Pascale. Front Pharmacol, 2016, 7: 287.

27. Lalani A-K, Li H, Heng D, et al. Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience [abstract]. In: 41st European Society for Medical Oncology Congress, 2016.

28. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2016, 27(Suppl 5): v58–68.

29. Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma. 2016. http: // uroweb.org/guideline/renal-cellcarcinoma/. Accessed 7 Nov 2016.

30. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (version 2.2017). 2016. http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 7 Nov 2016.

31. Jung KS, Cho J, Yoo KH, et al. Pazopanib for treatment of metastatic renal cell carcinoma with non-clear cell histology: single-arm, open label, multicenter, phase II study [abstract no. 577]. J Clin Oncol, 2016, 34(Suppl 2).

32. Buti S, Bersanelli M, Maines F, et al. First-line pazopanib in nonclear cell renal carcinoma: the Italian retrospective multicenter PANORAMA study [abstract no. e16081]. J Clin Oncol, 2016, 34(Suppl).

33. Matrana MR, Baiomy A, Campbell M, et al. Outcomes of patients with metastatic non-clearcell renal cell carcinoma treated with pazopanib. Clin Genitourin Cancer, 2016, 15(2): e205–8.

34. Costello BA, Ho TH, Tan W, et al. Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial) [abstract no. TPS4606]. J Clin Oncol, 2014, 32(Suppl 5).

35. Goebell P, Doehn C, Grullich C, et al. The PAZOREAL noninterventional study to assess efficacy and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma (mRCC) treatment landscape [abstract]. In: 41st European Society for Medical Oncology Congress, 2016.

36. Capri S, Porta C, Delea T. Cost-effectiveness of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian national health service perspective. Clin Ther, 2017, 39(3): 567–80.

37. Espinosa J, Gonzalez-Larriba JL, Maroto P, et al. Cost-utility analysis of pazopanib verses sunitinib as first-line treatment of metastatic renal cell carcinoma (MRCC) in Spain [abstract no. PCN107]. Value Health, 2014, 17(7): A632–3.

38. Delea TE, Amdahl J, Diaz J, et al. Costeffectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm, 2015, 21(1): 46–54.

39. Racsa PN,Whisman TR,Worley K. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin, 2015, 31(10): 1933–40.

40. Villa G, Hernandez-Pastor L-J. Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer, 2013, 13: 399.

41. Hansen RN, Hackshaw MD, Nagar SP, et al. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm, 2015, 21(1): 37–44.

42. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol, 2002, 20: 289– 6.

43. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol, 2013, 14: 141-148.

44. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2): 228–247.


Для цитирования:


Алексеев Б.Я., Шевчук И.М. Пазопаниб – препарат первой линии терапии у больных с метастатическим раком почки. Медицинский Совет. 2018;(10):70-76. https://doi.org/10.21518/2079-701X-2018-10-70-76

For citation:


Alekseev B.Y., Shevchuk I.M. Pazopanib as first-line therapy for patients with metastatic kidney cancer. Medical Council. 2018;(10):70-76. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-70-76

Просмотров: 110


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)